Is NCT06806033 recruiting in Torrance, CA?

Yes, NCT06806033 is currently recruiting participants at its Torrance, CA location. This diffuse large b-cell lymphoma clinical trial is actively enrolling qualified participants.

How do I join the diffuse large b-cell lymphoma clinical trial in Torrance?

To join this clinical trial in Torrance, complete the eligibility form on this page. A study coordinator will contact you to discuss next steps and determine if you qualify.

Is participation in this Torrance clinical trial free?

Yes, all study-related care is provided at no cost to qualified participants. Many studies also offer compensation for time and travel expenses.

Diffuse Large B-Cell Lymphoma Clinical Trial in Torrance, CA

About This Diffuse Large B-Cell Lymphoma Study in Torrance

The main goal of this trial is to study the frequency and severity of cytokine release syndrome (CRS) in participants with diffuse large B-cell lymphoma (DLBCL) who are using a combination of glofitamab + gemcitabine + oxaliplatin (Glofit-GemOx) followed by glofitamab-only treatment.

Sponsor: Hoffmann-La Roche

Who Can Participate

Inclusion Criteria

Histologically confirmed large B-cell lymphoma (de novo or transformed from FL) with one of the following diagnoses according to World Health Organization, fifth edition: DLBCL Not Otherwise Specified (NOS); High-Grade B-Cell Lymphoma (HGBL), NOS; DLBCL/HGBL with MYC and BCL2 rearrangements

R/R disease, defined as: relapsed = disease that has recurred following a response that lasted \>/= 6 months after completion of the last line of therapy; refractory = disease that did not respond to or that progressed \< 6 months after completion of the last line of therapy

At least one line of prior systemic therapy

Participants who have failed only one prior line of therapy must not be a candidate for high-dose chemotherapy followed by autologous stem cell transplant (ASCT)

At least one bi-dimensionally measurable (\> 1.5 cm) nodal lesion, or one bi-dimensionally measurable (\> 1 cm) extranodal lesion, as measured on CT scan

Eastern Cooperative Oncology Group (ECOG) status of 0, 1, or 2

According to the investigator's judgment, participants should be able to receive the step-up dose regimen in an outpatient setting

Adequate hematologic and renal function

Exclusion Criteria

Prior enrollment in Studies GO41943 (NCT04313608), GO41944 (STARGLO; NCT04408638), or Study GO44900 (NCT06624085)

Participant has failed only one prior line of therapy and is a candidate for stem cell transplantation

Any history of Waldenstrom's macroglobulinemia

Primary mediastinal B-cell lymphoma

History of severe allergic or anaphylactic reactions to humanized or murine monoclonal antibodies (or recombinant antibody-related fusion proteins) or known sensitivity or allergy to murine products

Contraindication to obinutuzumab, gemcitabine or oxaliplatin, or tocilizumab

Prior treatment with glofitamab or other bispecific antibodies targeting both CD20 and CD3

Prior treatment with gemcitabine or oxaliplatin

Peripheral neuropathy or paresthesia assessed to be Grade \>/= 2 according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) v5.0 at enrollment

Treatment with radiotherapy, chemotherapy, immunotherapy, immunosuppressive therapy, or any investigational agent for the purposes of treating cancer within 2 weeks prior to first study treatment

Treatment with monoclonal antibodies for the purposes of treating cancer within 4 weeks prior to first study treatment

Primary or secondary CNS lymphoma at the time of recruitment

Prior CNS involvement that has been definitively treated and confirmed via magnetic resonance imaging (MRI) or cerebrospinal fluid analysis to be in complete remission is permissible

Current or history of CNS disease, such as stroke, epilepsy, CNS vasculitis, or neurodegenerative disease

History of other primary malignancy, with exceptions defined by the protocol

Significant or extensive cardiovascular disease

Significant pulmonary disease (including moderate or severe obstructive pulmonary disease)

Known active bacterial, viral, fungal, mycobacterial, parasitic, or other infection (excluding fungal infections of nail beds) at study enrollment or any major episode of infection (as evaluated by the investigator) within 4 weeks prior to the first study treatment

Positive for: severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2); tuberculosis; hepatitis B virus (HBV); hepatitis C virus (HCV); chronic active Epstein-Barr viral infection

Known or suspected history of hemophagocytic lymphohistiocytosis (HLH) or progressive multifocal leukoencephalopathy

Adverse events from prior anti-cancer therapy that have not resolved to Grade 1 or better (with the exception of alopecia and anorexia)

Administration of a live, attenuated vaccine within 4 weeks before first study treatment administration or anticipation that such a live, attenuated vaccine will be required during the study

Prior solid organ transplantation or prior allogenic stem cell transplant

Active autoimmune disease requiring treatment

Prior treatment with systemic immunosuppressive medications (including, but not limited to, cyclophosphamide, azathioprine, methotrexate, thalidomide, and antitumor necrosis factor agents), within 4 weeks prior to first dose of study treatment

Ongoing systemic corticosteroid use which, in the opinion of the investigator, puts the participant at increased risk of steroid-related iatrogenic adrenal insufficiency

Recent major surgery (within 4 weeks before the first study treatment) other than for diagnosis

Clinically significant history of cirrhotic liver disease

Any other diseases, metabolic dysfunction, physical examination finding, or clinical laboratory finding giving reasonable suspicion of a disease or condition that contraindicates the use of an investigational drug or that may affect the interpretation of the results or renders the participant at high-risk from treatment complications

Pregnancy or breastfeeding, or intention of becoming pregnant during the study or within 18 months after the final dose of study treatment

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in Torrance?

Yes, this clinical trial (NCT06806033) has an active research site in Torrance, CA that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

Diffuse Large B-Cell Lymphoma Treatment Options in Torrance, CA

If you're searching for diffuse large b-cell lymphoma treatment options in Torrance, CA, this clinical trial (NCT06806033) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our Torrance research site is actively enrolling participants for this phase 2 clinical trial. You'll receive care from experienced diffuse large b-cell lymphoma specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all diffuse large b-cell lymphoma clinical trials near you to find additional studies recruiting in your area.

Diffuse Large B-Cell Lymphoma Clinical Trial in Torrance, CA

Expert Care in Torrance

IRB Approved

No-Cost Care

Apply for This Torrance Location

Why Participate?

Simple Process